UK open to talks over vaccine waivers but is still sceptical
AstraZeneca says it has already shared its IP and know-how with dozens of partners for its Covid-19 vaccine
London — Britain is open to talks with the US and other World Trade Organization (WTO) members on the issue of intellectual property (IP) waivers for Covid-19 vaccines, a government spokesperson said after pressure from charities to back US proposals.
Last week, US President Joe Biden threw his support behind waiving IP rights for Covid-19 vaccines.
British and EU officials have been sceptical about the usefulness of the proposal, while saying they are prepared to discuss it.
“We are engaging with the US and other WTO members constructively on the Agreement on Trade-Related Aspects of Intellectual Property Rights waiver issue, but we need to act now to expand production and distribution worldwide,” the British government spokesperson said, adding that WTO negotiations on the waiver would be lengthy as they would need unanimous support.
“So, while we will constructively engage in the IP discussions, we must continue to push ahead with action now, including voluntary licensing agreements for vaccines.”
Britain has promised to donate surplus vaccines to other countries when it is able to, but says it has no spare shots to give at the moment.
About two thirds of the adult population of Britain has received a dose of a Covid-19 vaccine, while Britain has ordered 517-million doses in all.
Hundreds of charities, academics and politicians signed a letter to Prime Minister Boris Johnson this week, calling on him to back Biden’s move on IP waivers.
Pharmaceutical companies and other critics of the waiver move say producing Covid-19 vaccines is complex and setting up production at new facilities would divert resources from efforts to boost production at existing sites, potentially compromising safety.
On Tuesday, about a dozen protesters sat outside AstraZeneca’s headquarters in Cambridge, England, to coincide with the firm’s AGM. Some chained themselves to the doors and others unfurled a banner saying “People’s Vaccine Not Profit Vaccine”.
AstraZeneca, which has entered into manufacturing partnerships to produce Oxford University’s vaccine candidate globally, has pledged not to profit from sales of the vaccine during the pandemic, though the campaigners highlight that the company can determine when that pledge ends.
Asked about the British government’s stance, an AstraZeneca spokesperson said the company agreed that the “extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures”, and that this has already informed its approach.
“We have established 20 supply lines spread across the globe and we have shared the IP and know-how with dozens of partners,” the spokesperson said. “In fact, our model is similar to what an open IP model could look like.”
AstraZeneca CEO Pascal Soriot said in April that it would maintain its no-profit pledge into 2022, and would keep no-profit or modest pricing for parts of the world thereafter.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.